leisure time -WSS

leisure time

author：Wikipedia 2025-09-09 05:35:42 - browse：32193

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Biotech venture capitalists face new demands from investors

WSS

Extreme heat events are a public health emergency

A clever new way to fix Medicaid and graduate medical education

Ambulance rides for just $100? Advisers want major billing fixes

Copay coupons to count toward deductibles, after Biden court move

EU regulator recommends expanding Mounjaro approval to obesity

Francis Collins on trust in science and how Covid communications failed

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Apple is now the first public company to be valued at $3 trillion

FDA approves Recor Medical high blood pressure device

The high cost of giving birth even with insurance

Abortion clinic in Cancun will cater to Americans

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Will General Catalyst be the first of many hospital takeovers?

Peter Hotez and the public health issue of online harassment

Research misconduct: Proposed new rules face resistance

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Biotech incubator Curie.Bio graduates its first startup

Wikipedia

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Parkinson’s finding may lead to tests and, someday, treatments

STAT Executive Editor Rick Berke on STAT's 8th birthday

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Dewpoint Therapeutics lays off staff after losing partnerships

MoonLake credibility takes another hit with mid

focus

leisure time

hotspot

knowledge